NCT04551482 is a Phase 2 clinical trial of Oxytocin nasal spray in Obesity, Adolescent, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04551482?

NCT04551482 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04551482?

Interventions in NCT04551482: Oxytocin nasal spray, Placebo.

What condition does NCT04551482 study?

NCT04551482 studies Obesity, Adolescent, Oxytocin.

Is NCT04551482 still recruiting?

NCT04551482 is currently recruiting now. Last updated 20 July 2025.

Last reviewed 2025-07-20 · How we verify

NCT04551482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxytocin for Weight Loss in Adolescents

Recruiting now Phase 2 Last updated 20 July 2025

What this trial tests

Phase 2 trial testing Oxytocin nasal spray in Obesity, Adolescent in 75 participants. Currently enrolling.

Timeline

28 July 2021

Primary endpoint
30 June 2026

31 March 2027

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	75
Start date	28 July 2021
Primary completion	30 June 2026
Estimated completion	31 March 2027
Sites	1 location across United States

Drugs / interventions tested

Oxytocin nasal spray — full drug profile →
Placebo

Conditions studied

Obesity, Adolescent — all drugs for Obesity, Adolescent →
Oxytocin — all drugs for Oxytocin →

Sponsor

Massachusetts General Hospital

Who can join

Adults 10 to 18, any sex, with Obesity, Adolescent or Oxytocin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans.
Kerem L, Lawson EA. · · 2021 · cited 68× · PMID 34299356 · DOI 10.3390/ijms22147737
Pituitary crosstalk with bone, adipose tissue and brain.
Zaidi M, Yuen T, Kim SM. · · 2023 · cited 31× · PMID 37715028 · DOI 10.1038/s41574-023-00894-5
The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease.
Aulinas A, Lawson EA. · · 2025 · cited 9× · PMID 39985439 · DOI 10.1210/endrev/bnaf008

Verify or expand the search:

Other trials of Oxytocin nasal spray

Trials testing the same drug.

NCT07162584 — Oxytocin and Human Defensive Responses in a Dynamic Situation · NA · recruiting
NCT06194851 — Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD · Phase 2 · recruiting
NCT05934812 — Intranasal Oxytocin in Youth With Autism · Phase 2 · not yet recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT06332066 — Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness · Phase 1 · unknown

Other recruiting trials for Obesity, Adolescent

Currently open trials in the same condition.

NCT06920862 — Multi-Modal Digital Interventions for Adolescent Weight Management · NA · recruiting
NCT06822387 — Health Without Barriers/Salud Sin Barreras- Northern Colorado · NA · recruiting
NCT06309121 — Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents · NA · active not recruiting
NCT05982847 — National Blood Pressure Screening in Children to Improve Paediatric Healthcare in South Africa · recruiting
NCT06515288 — Nutrition Goes to School: a School-based Nutrition Intervention to Promote Healthy Eating Behaviour Among Adolescents · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04551482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 20 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04551482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing